Hortobagyi GN - Search Results

1

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Piccart M, et al. Among authors: hortobagyi gn. Ann Oncol. 2014 Dec;25(12):2357-2362. doi: 10.1093/annonc/mdu456. Epub 2014 Sep 17. Ann Oncol. 2014. PMID: 25231953 Free PMC article. Clinical Trial.

2

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Buzdar AU, et al. Among authors: hortobagyi gn. J Clin Oncol. 1992 Oct;10(10):1540-6. doi: 10.1200/JCO.1992.10.10.1540. J Clin Oncol. 1992. PMID: 1403033 Clinical Trial.

3

Bone metastasis in breast cancer.

Theriault RL, Hortobagyi GN. Theriault RL, et al. Among authors: hortobagyi gn. Anticancer Drugs. 1992 Oct;3(5):455-62. doi: 10.1097/00001813-199210000-00002. Anticancer Drugs. 1992. PMID: 1450438 Review.

4

Treatment of locally advanced breast cancer.

Booser DJ, Hortobagyi GN. Booser DJ, et al. Among authors: hortobagyi gn. Semin Oncol. 1992 Jun;19(3):278-85. Semin Oncol. 1992. PMID: 1609294 Review.

5

Elliptinium acetate in metastatic breast cancer--a phase II study.

Buzdar AU, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G, Lichtiger B. Buzdar AU, et al. Among authors: hortobagyi gn. Oncology. 1990;47(2):101-4. doi: 10.1159/000226797. Oncology. 1990. PMID: 2314820

6

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.

Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Dunphy FR, et al. Among authors: hortobagyi gn. J Clin Oncol. 1990 Jul;8(7):1207-16. doi: 10.1200/JCO.1990.8.7.1207. J Clin Oncol. 1990. PMID: 2358837 Clinical Trial.

7

Use of tamoxifen for breast cancer: twenty-eight years later.

Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Jaiyesimi IA, et al. Among authors: hortobagyi gn. J Clin Oncol. 1995 Feb;13(2):513-29. doi: 10.1200/JCO.1995.13.2.513. J Clin Oncol. 1995. PMID: 7844613 Review.

8

Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.

Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Buzdar AU, et al. Among authors: hortobagyi gn. J Clin Oncol. 1994 Jan;12(1):50-4. doi: 10.1200/JCO.1994.12.1.50. J Clin Oncol. 1994. PMID: 8270984 Clinical Trial.

9

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Valero V, et al. Among authors: hortobagyi gn. J Clin Oncol. 1995 Dec;13(12):2886-94. doi: 10.1200/JCO.1995.13.12.2886. J Clin Oncol. 1995. PMID: 8523051 Clinical Trial.

10

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Greenberg PA, et al. Among authors: hortobagyi gn. J Clin Oncol. 1996 Aug;14(8):2197-205. doi: 10.1200/JCO.1996.14.8.2197. J Clin Oncol. 1996. PMID: 8708708

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,108 results

Search Page

Filters